Patents by Inventor Tsze Tsang

Tsze Tsang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
    Publication number: 20230150942
    Abstract: The present disclosure provides compounds, pharmaceutical compositions, and methods for the treatment of cancer and fibrosis. The disclosed pharmaceutical compositions may include one or more pyrazolyl-containing compounds, or a derivative thereof.
    Type: Application
    Filed: December 5, 2022
    Publication date: May 18, 2023
    Inventors: Csaba PETO, Bhairavi TOLANI, Gavitt WOODARD, Tsze TSANG, Michael MANN, David M. JABLONS, Biao HE
  • Compounds and compositions for the treatment of cancer
    Patent number: 11560356
    Abstract: The present disclosure provides compounds, pharmaceutical compositions, and methods for the treatment of cancer and fibrosis. The disclosed pharmaceutical compositions may include one or more pyrazolyl-containing compounds, or a derivative thereof.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: January 24, 2023
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, RESCUE THERAPEUTICS, INC.
    Inventors: Csaba Peto, Bhairavi Tolani, Gavitt Woodard, Tsze Tsang, Michael Mann, David M. Jablons, Biao He
  • Phthalazine Derivatives as Inhibitors of PARP1, PARP2, and/or Tubulin Useful for the Treatment of Cancer
    Publication number: 20220402894
    Abstract: The application relates to phthalazine derivatives of formula (I) which are inhibitors of PARP1, PARP2 and/or tubulin and thus useful for the treatment of cancer. Also disclosed are pharmaceutical formulations containing such compounds, as well as combinations of these compounds with at least one additional therapeutic agent.
    Type: Application
    Filed: July 15, 2021
    Publication date: December 22, 2022
    Inventors: Csaba J. PETO, David M. Jablons, Tsze Tsang, Hassan Lemjabbar-Alaoui
  • Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer
    Patent number: 11072600
    Abstract: The application relates to phthalazine derivatives of formula (I) which are inhibitors of PARP1, PARP2 and/or tubulin and thus useful for the treatment of cancer. Also disclosed are pharmaceutical formulations containing such compounds, as well as combinations of these compounds with at least one additional therapeutic agent.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: July 27, 2021
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, ATLASMEDX, INC.
    Inventors: Csaba J. Peto, David M. Jablons, Tsze Tsang, Hassan Lemjabbar-Alaoui
  • Compounds and Compositions for the Treatment of Cancer
    Publication number: 20210009523
    Abstract: The present disclosure provides compounds, pharmaceutical compositions, and methods for the treatment of cancer and fibrosis. The disclosed pharmaceutical compositions may include one or more pyrazolyl-containing compounds, or a derivative thereof.
    Type: Application
    Filed: June 28, 2017
    Publication date: January 14, 2021
    Inventors: Csaba Peto, Bhairavi Tolani, Gavitt Woodard, Tsze Tsang, Michael Mann, David M. Jablons, Biao He
  • Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer
    Patent number: 10640493
    Abstract: This invention provides, among other things, compounds useful for treating diseases such as cancer, pharmaceutical formulations containing such compounds, as well as combinations of these compounds with at least one additional therapeutic agent.
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: May 5, 2020
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, ATLASMEDX, INC.
    Inventors: Csaba J. Peto, David M. Jablons, Tsze Tsang, Hassan Lemjabbar-Alaoui
  • Phthalazine Derivatives as Inhibitors of PARP1, PARP2, and/or Tubulin Useful for the Treatment of Cancer
    Publication number: 20190352283
    Abstract: This invention provides, among other things, compounds useful for treating diseases such as cancer, pharmaceutical formulations containing such compounds, as well as combinations of these compounds with at least one additional therapeutic agent.
    Type: Application
    Filed: July 30, 2019
    Publication date: November 21, 2019
    Inventors: Csaba J. PETO, David M. JABLONS, Tsze TSANG, Hassan LEMJABBAR-ALAOUI
  • Phthalazine Derivatives as Inhibitors of PARP1, PARP2, and/or Tubulin Useful for the Treatment of Cancer
    Publication number: 20190337928
    Abstract: The application relates to phthalazine derivatives of formula (I) which are inhibitors of PARP1, PARP2 and/or tubulin and thus useful for the treatment of cancer. Also disclosed are pharmaceutical formulations containing such compounds, as well as combinations of these compounds with at least one additional therapeutic agent.
    Type: Application
    Filed: June 23, 2017
    Publication date: November 7, 2019
    Inventors: Csaba J. PETO, David M. JABLONS, Tsze TSANG, Hassan LEMJABBAR-ALAOUI
  • Raf Modulators and Methods of Use
    Publication number: 20080009488
    Abstract: The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases, particularly Raf. Methods of using the compounds and pharmaceutical compositions thereof to treat kinase-dependent diseases and conditions are also an aspect of the invention.
    Type: Application
    Filed: March 25, 2005
    Publication date: January 10, 2008
    Applicant: EXELIXIS, INC.
    Inventors: Neel Anand, Charles Blazey, Owen Bowles, Joerg Bussenius, Simona Costanzo, Jeffry Curtis, Larisa Dubenko, Abigail Kennedy, Steven Defina, Angie Kim, Jean-Claire Manalo, Csaba Peto, Kenneth Rice, Tsze Tsang, Anagha Joshi
  • Anaplastic lymphoma kinase modulators and methods of use
    Publication number: 20070032515
    Abstract: The present invention comprises compounds and pharmaceutical compositions comprising the compounds that are inhibitors of ALK. The invention also comprises methods of using the compounds and compositions to treat diseases mediated by ALK, including diseases such as cancer, immunological disorders, cardiovascular diseases, and other degenerative disorders.
    Type: Application
    Filed: July 23, 2004
    Publication date: February 8, 2007
    Applicant: Exelixis, Inc.
    Inventors: Neel Anand, Charles Blazey, Owen Bowles, Joerg Bussenius, Simona Costanzo, Jeffry Curtis, Larisa Dubenko, Abigail Kennedy, Richard Khoury, Angie Kim, Jean-Claire Manalo, Csaba Peto, Kenneth Rice, Tsze Tsang
  • Protein kinase modulators and methods of use
    Publication number: 20060211709
    Abstract: Substituted aryl 1,4-pyrazine derivatives and their use in treating anxiety disorders, depression and stress related disorders are disclosed.
    Type: Application
    Filed: May 2, 2003
    Publication date: September 21, 2006
    Inventors: Chris Buhr, Tae-Gon Baik, Sunghoon Ma, Zerom Tesfai, Longcheng Wang, Erick Co, Sergey Epshteyn, Abigail Kennedy, Baili Chen, Larisa Dubenko, Neel Anand, Tsze Tsang, John Nuss, Csabaj Peto, Kenneth Rice, Mohamed Ibrahim, Xian Shi, James Leahy, Jeff Chen, Lisa Dalrymple, Timothy Forsyth, Tai Huynh, Grace Mann, Larry Mann, Craig Takeuchi
  • Receptor-type kinase modulators and methods of use
    Publication number: 20060069077
    Abstract: The present invention provides compounds for modulating receptor kinase activity, particularly ephrin and EGFR, and methods of treating diseases mediated by receptor kinase activity utilizing the compounds and pharmaceutical compositions thereof. Diseases mediated by receptor kinase activity include, but are not limited to, diseases characterized in part by abnormal levels of cell proliferation (i.e. tumor growth), programmed cell death (apoptosis), cell migration and invasion and angiogenesis associated with tumor growth. Compounds of the invention include “spectrum selective” kinase modulators, compounds that inhibit, regulate and/or modulate signal transduction across subfamilies of receptor-type tyrosine kinases, including ephrin and EGFR.
    Type: Application
    Filed: July 14, 2003
    Publication date: March 30, 2006
    Inventors: Kenneth Rice, Neel Anand, Joerg Bussenius, Simona Costanzo, Abigail Kennedy, Angie Kim, Csaba Peto, Tsze Tsang, Charles Blazey